Erasca (ERAS)
(Delayed Data from NSDQ)
$2.17 USD
-0.01 (-0.46%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $2.17 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
Erasca, Inc. [ERAS]
Reports for Purchase
Showing records 1 - 5 ( 5 total )
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Multiple MAPK Catalysts May Provide Significant Upside in 2024; Reit Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Naporafenib Leads MAPK Assault with Data in 2/4Q24; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress and Prioritization Refine MAPK Assault Strategy; Reit Buy and Lowering Our PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Rich Catalyst Calendar Looks to Showcase an Assault on MAPK; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
An Oncogenic MAPK Assault on All Fronts; Initiating with a Buy Rating and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
|